IL-17 Aggravates Pseudomonas aeruginosa Airway Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Authors:
Open Access
- 13 January 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 811803
Abstract
Pseudomonas aeruginosa airway infection increases risks of exacerbations and mortality in chronic obstructive pulmonary disease (COPD). We aimed to elucidate the role of IL-17 in the pathogenesis. We examined the expression and influences of IL-23/IL-17A in patients with stable COPD (n = 33) or acute COPD exacerbations with P. aeruginosa infection (n = 34). A mouse model of COPD (C57BL/6) was used to investigate the role of IL-17A in host inflammatory responses against P. aeruginosa infection through the application of IL-17A–neutralizing antibody or recombinant IL-17A. We found that P. aeruginosa infection increased IL-23/17A signaling in lungs of both COPD patients and COPD mouse models. When COPD mouse models were treated with neutralizing antibody targeting IL-17A, P. aeruginosa induced a significantly less polymorphonuclear leukocyte infiltration and less bacterial burden in their lungs compared to those of untreated counterparts. The lung function was also improved by neutralizing antibody. Furthermore, IL-17A-signaling blockade significantly reduced the expression of pro-inflammatory cytokine IL-1β, IL-18, TNF-α, CXCL1, CXCL15 and MMP-9, and increased the expression of anti-inflammatory cytokine IL-10 and IL-1Ra. The application of mouse recombinant IL-17A exacerbated P. aeruginosa-mediated inflammatory responses and pulmonary dysfunction in COPD mouse models. A cytokine protein array revealed that the expression of retinol binding protein 4 (RBP4) was down-regulated by IL-17A, and exogenous RBP4-recombinant protein resulted in a decrease in the severity of P. aeruginosa-induced airway dysfunction. Concurrent application of IL-17A-neutralizing antibody and ciprofloxacin attenuated airway inflammation and ventilation after inoculation of P. aeruginosa in COPD mouse models. Our results revealed that IL-17 plays a detrimental role in the pathogenesis of P. aeruginosa airway infection during acute exacerbations of COPD. Targeting IL-17A is a potential therapeutic strategy in controlling the outcomes of P. aeruginosa infection in COPD patients.Keywords
Funding Information
- National Natural Science Foundation of China (81873402, 81970006)
- Science and Technology Commission of Shanghai Municipality (20ZR1444300, 20Y11902400, 20Z11900903)
- Shanghai Municipal Health Commission (2019SY042)
This publication has 46 references indexed in Scilit:
- Low Serum retinol-binding protein-4 levels in acute exacerbations of chronic obstructive pulmonary disease at intensive care unit admission is a predictor of mortality in elderly patientsJournal of Inflammation, 2013
- Activation of inflammasome signaling mediates pathology of acute P. aeruginosa pneumoniaJournal of Clinical Investigation, 2013
- IL-17RA Is Required for CCL2 Expression, Macrophage Recruitment, and Emphysema in Response to Cigarette SmokePLOS ONE, 2011
- Functional Specialization of Interleukin-17 Family MembersImmunity, 2011
- ChronicPseudomonas aeruginosaInfection in Chronic Obstructive Pulmonary DiseaseClinical Infectious Diseases, 2008
- IL-23 mediates inflammatory responses to mucoidPseudomonas aeruginosalung infection in miceAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Involvement of Toll-like receptor 5 in the recognition of flagellated bacteriaProceedings of the National Academy of Sciences, 2006
- The IL-23/IL-17 axis in inflammationJournal of Clinical Investigation, 2006
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992
- Tissue Destruction by NeutrophilsNew England Journal of Medicine, 1989